In asymptomatic patients with T2DM and heart stress, 3-month treatment with SGLT2i or GLP1-RA significantly reduced NT-proBNP levels by 2.3% (p=0.049) and 6.5% (p=0.002), respectively.
Observational (n=100)
Yes
Does short-term treatment with SGLT2i or GLP1-RA reduce plasma NT-proBNP levels in asymptomatic T2DM patients with elevated blood pressure and heart stress?
Short-term treatment with SGLT2i or GLP1-RA significantly reduces NT-proBNP levels in asymptomatic T2DM patients with subclinical cardiac organ damage, suggesting an improvement in cardiac wall stress.
p-value: p=0.049 (SGLT2i), 0.002 (GLP1-RA)
Objective: We investigated the effect of a short-term treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) on N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in asymptomatic T2DM patients without known heart failure, but with elevated blood pressure and heart stress (HS), a subclinical cardiac organ damage. Design and method: Multicenter observational longitudinal “real-life” study on 100 consecutive patients. Plasma NT-proBNP was assessed at baseline, before starting SGLT2i/GLP1-RA and after a 3-month follow-up. For the analyses, NT-proBNP levels were adjusted for estimated glomerular filtration rate (eGFR) in SGLT2i group and for body mass index (BMI) in GLP1-RA group. Results: Mean age: 73.3±7.7 years. Baseline median NT-proBNP: 192.5 (114.0-966.0) pg/mL. At follow-up, we found a slight reduction in adjusted NT-proBNP in the SGLT2i group (n° 57 patients) (-2.3%; p=0.049). Adjusted NT-proBNP showed a statistically significant decrease (-6.5%; p=0.002) within the entire GLP1-RA group (n° 43 patients), with a significant greater reduction in patients with higher baseline NT-proBNP (-13.3%; <0.001). In both subgroups, patients aged <70 years showed a greater reduction in NTproBNP.Conclusions: In asymptomatic patients with T2DM and HS, SGLT2i and especially GLP1-RA led to a slight but significant improvement in cardiac wall stress, as evidenced by the NT-proBNP decrease.
Spannella et al. (Fri,) conducted a observational in Type 2 diabetes mellitus with elevated blood pressure and heart stress (n=100). SGLT2-inhibitors and GLP1-receptor agonists vs. Baseline was evaluated on Change in adjusted NT-proBNP levels (p=0.049 (SGLT2i), 0.002 (GLP1-RA)). In asymptomatic patients with T2DM and heart stress, 3-month treatment with SGLT2i or GLP1-RA significantly reduced NT-proBNP levels by 2.3% (p=0.049) and 6.5% (p=0.002), respectively.